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Abstract
Background: To evaluate the quantitative changes of retinal pigment epithelial (RPE) atrophy during 3-year
follow-up period of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV).
Methods: We retrospectively reviewed consecutive 100 Japanese patients with unilateral symptomatic
treatment-naïve PCV who received ranibizumab monotherapy for 3 years. Color fundus photography,
spectral-domain optical coherence tomography, and fundus autofluorescence were evaluated for RPE atrophy.
Multiple regression analysis was performed to investigate the predictive factors found during univariate analysis to
identify an association with increased RPE atrophic areas. RPE atrophic areas overlapping PCV lesions were
measured.
Results: The mean (standard deviation) number of injections was 11.4 (4.50). RPE atrophic area enlarged to 2.91
(5.41 mm2) 3 years after the first injection from 1.22 (1.72 mm2) at baseline, which differed significantly (P = 0.012).
Multiple regression analysis showed that larger PCV lesions and larger RPE atrophic areas at baseline were
associated with increased RPE atrophic areas. RPE atrophic area overlapping the baseline PCV lesions significantly
increased during 3-year follow-up period, whereas RPE atrophic area not overlapping the baseline PCV lesions did
not increase significantly.
Conclusion: RPE atrophy progresses in eyes with PCV during ranibizumab monotherapy and the tendency for
development of RPE atrophy within the PCV lesions.
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Background
Polypoidal choroidal vasculopathy (PCV) was classically de-
fined based on indocyanine green angiography (ICGA) and
clinically seen as orange “polyplike” structures [1, 2], which
are present at the terminal of a network of branching ves-
sels. Pachychoroid pigment epitheliopathy is a recent newly
described clinical entity characterized by a range of retinal
pigment epithelial (RPE) abnormalities overlying the areas
of choroidal thickening [3]. It is believed to reside within a
spectrum of diseases including central serous chorioretino-
pathy, which involves choroidal congestion and choroidal
hyperpermeability, resulting in focal RPE atrophy [3]. Long-
standing “silent” pachychoroid pigment epitheliopathy may
develop type 1 choroidal neovascularization (CNV), and ul-
timately PCV [4]. Progression of RPE atrophy is common
in the natural history of PCV [5]. Polypoidal lesions and
branching vascular networks were hypoautofluorescent on
fundus autofluorescence (FAF) images, suggesting that neo-
vascular lesion may directly affect overlying RPE cells in
eyes with PCV [6, 7].
Vascular endothelial growth factor (VEGF) plays a crit-
ical role in both survival and maintenance of RPE integ-
rity [8], and RPE-derived VEGF is an essential factor for
maintenance of choriocapillaris [9, 10]. The SEVEN-UP
study [11, 12] reported that most eyes with age-related
macular degeneration (AMD) require anti-VEGF treat-
ment over a long period, and the constant neutralization
of VEGF may cause RPE atrophy and choriocapillary
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atrophy threatening visual conditions. The Comparison
of Age-related Macular Degeneration Treatments Trials
(CATT) [13, 14] also reported that the incidence of geo-
graphic atrophy (GA) was 18.3 % during 2 years of anti-
VEGF treatment.
However, little information of RPE atrophy during
anti-VEGF treatment is available about Asian patients.
Recently, Kuroda and associates [15] studied Japanese
patients with treatment-naïve neovascular AMD treated
with ranibizumab (Lucentis, Genentech Inc., South San
Francisco, CA), and concluded that RPE atrophy devel-
oped during ranibizumab treatment less frequently in
Japanese patients compared with Caucasian patients and
RPE atrophy progression rate was significantly faster in
typical AMD than in PCV.
In the current study, we especially focused on the
qualitative changes in RPE atrophy during 3-year follow-
up period of ranibizumab monotherapy in eyes with
PCV and investigated the characteristics of changing
RPE atrophy.
Methods
The current research followed the tenets of the Declar-
ation of Helsinki, and all patients provided informed
consent after explanation of the study protocol. The in-
stitutional review board at Ohtsuka Eye Hospital ap-
proved this retrospective study.
Data were collected retrospectively from consecutive
Japanese patients with newly diagnosed, symptomatic,
unilateral, treatment-naïve PCV at the Ohtsuka Eye Hos-
pital who were treated with ranibizumab monotherapy
and followed for 3 years. Treatment consisted of 0.5-mg
intravitreal ranibizumab injection (IVR) for 3 months
followed by as-needed reinjections based on monthly ex-
aminations between June 2010 and December 2012.
There were no exclusion criteria for baseline VA or le-
sion size; however, eyes were excluded if there was a
massive subretinal hemorrhage or subpigment epithelial
hemorrhage that obscured the FAF findings, a spherical
equivalent of -6.0 diopters or less or chorioretinal atro-
phic changes secondary to other disorders, and a history
of treatment with anti-VEGF therapy and/or photo-
dynamic therapy in the fellow eye.
PCV was defined as the presence of one or multiple
focal areas of hyperfluorescence from the inner chor-
oidal vessels within the first 6 min after injection of in-
docyanine green with or without an associated
branching vascular network [16]. All patients underwent
comprehensive ocular examinations including measure-
ment of the best-corrected visual acuity (VA) using a
Landolt ring chart and intraocular pressure, indirect
ophtamoscopy, slit-lamp biomicroscopy with a preset
lens, color fundus photography, digital simultaneous
fluorescein angiography and ICGA and FAF imaging
with a confocal scanning laser ophthalmoscope (HRA-2,
Heidelberg Engineering Inc., Heidelberg, Germany), and
spectral-domain optical coherence tomography (OCT)
(Spectralis, Heidelberg Engineering Inc.), at the baseline
examination. Generally, the ranibizumab first was
injected on the same day as the baseline examination
after the patients provided informed consent. FAF im-
aging was performed at baseline, 1 month after the three
monthly injections, 12 months after the first IVR, and
then every 6 months during the follow-up period.
The FAF images were acquired using a 488-nm excita-
tion wave length, and emitted fluorescence signals were
detected between 500 to 700 nm using the high-speed
mode. The field of view was set at 30 × 30° with digital
image resolution of 768 × 768 pixels and centered on
the macula. The dramatic decrease of the FAF signal in
the area of RPE atrophy compared with the nonatrophic
retinal areas is used by the Region Finder, which can
semiautomatically quantify atrophic areas and allows
FAF images to be processed directly [17], for segmenta-
tion of the atrophic areas. Retinal blood vessels with in-
tensities similar to those of the atrophic areas were
excluded using the retinal blood vessel detection tool.
Because of luteal pigment, blue-light FAF intensities typ-
ically decrease in the fovea. Although atrophic areas ex-
hibit an even lower FAF intensity than the central
macula, foveal involvement can be challenging to iden-
tify. Therefore, readers were instructed to use con-
straints while using the corresponding blue reflectance
(488 nm) and near-infrared reflectance (820 nm) images
to improve visualization of the foveal lesion boundary.
Hypofluorescent signals on FAF images also are seen
with fresh hemorrhages, lipid deposits, dense hyperpig-
mentation, RPE tears, and some forms of hard drusen.
To eliminate such lesions, fundus photos and OCT find-
ings were used as references. For each visit, the size of
the total atrophic area was measured using the semiau-
tomatic procedure. Two examiners (TH, HK) measured
the RPE atrophic areas on all FAF images, and an inter-
mediate value was adopted as the value of RPE atrophic
area. To determine the inter-examiner (T.H., H.K.) reli-
ability in the measurement of the RPE atrophic areas,
the interclass correlation was calculated. Intra-examiner
reliability also was evaluated by the intraclass correl-
ation, which was calculated from the measurements of
the RPE atrophic areas on 50 randomly selected cases
on different two days by one examiner (T.H.).
Several possible factors were considered that may
affect changes in the RPE atrophic area during 3-year
ranibizumab therapy. The data recorded were age, gen-
der, baseline VA, baseline areas of PCV lesions including
polypoidal lesions and branching vascular networks,
baseline location of PCV lesion, baseline RPE atrophic
area in the treated and fellow eyes, presence of
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hemorrhages exceeding two optic disc areas at baseline,
presence of a serous or hemorrhagic RPE detachment
exceeding one optic disc area at baseline, number of
IVR, and presence of intraretinal and subretinal fluid at
baseline. To investigate the association between the
change of RPE atrophic area during ranibizumab therapy
and the factors measured on a continuous scale (i.e., age,
VA, PCV lesion area, RPE atrophic area, and number of
injections), simple regression analysis was performed
(Table 2). In the categorical factors, the differences in
change of RPE atrophic area during ranibizumab therapy
between two mean values of categories or among more
than three categories were analyzed using the Student’s
t-test or one-way analysis of variance test, respectively
(Table 2). To investigate the predictive factors of in-
creased RPE atrophic area during 3-year ranibizumab
therapy, multiple regression analysis was performed
using the factors that achieved P < 0.2 in the univari-
ate analysis. The logarithm of the minimum angle of
resolution (logMAR) VA converted from the decimal
VA was used to analyze the VA. All data analyses
were performed using SAS version 9.3 software (SAS
Inc., Cary, NC).
To investigate the tendency that RPE atrophy may
progress over PCV lesions including polypoidal lesions
and branching vascular networks during ranibizumab
therapy, areas of RPE atrophy overlapping baseline PCV
lesions were measured. The PCV lesions on the baseline
ICGA images and areas of RPE atrophy on the FAF im-
ages were highlighted. Using an optic disc and retinal
vessels as landmarks to superimpose the two images, the
two images then were overlapped on the ImageJ soft-
ware (version 1.48, National Institutes of Health, Be-
thesda, MD) and the areas of RPE atrophy overlapping
and not overlapping PCV lesions were calculated.
Results
Table 1 shows the baseline clinical characteristics of 100
patients and 3-year results of ranibizumab therapy. The
mean (standard deviation) logMAR VA improved signifi-
cantly (P = 0.027) from 0.33 (0.36) to 0.23 (0.31). The
mean number of injections including the initial three
monthly injections administered during the follow-up
period was 11.4 (4.5). Fourteen (14 %) patients partici-
pated in our previous study [18] in which prognostic fac-
tors of 2-year outcomes of ranibizumab therapy for PCV
were investigated.
RPE atrophy was found in 84 (84 %) eyes and not
found in 16 (16 %) eyes at baseline. In all 100 eyes, RPE
atrophic area progressed significantly (P = 0.012) from
1.22 (1.72 mm2) at baseline to 2.91 (5.41 mm2) 3 years
after the first IVR (Fig. 1). Before using the Student’s t-
test to compare the values between baseline and 3 years
after the first IVR, a normal distribution of the data was
confirmed using the Kolmogrov Smirnov test. In 84 eyes
with RPE atrophy at baseline and 16 eyes without RPE
atrophy at baseline, RPE atrophy area increased signifi-
cantly (P = 0.026 and P = 0.001, respectively) (Fig. 1). In
the fellow eyes, the RPE atrophic area slightly increased
during 3-year follow-up period, which did not differ
significantly. The rate by which the area increased an-
nually in the treated eyes [0.56 (1.37 mm2)] was
Table 1 Baseline characteristics and three-year outcomes during ranibizumab monotherapy [mean (SD)]
All eyes
(n = 100)
Baseline RPE atrophy in treated eye
Absent (n = 16) Present (n = 84)
Age (years) 71.5 (9.5) 70.0 (8.9) 71.8 (9.7)
RPE atrophy area (mm2)
Baseline 1.22 (1.72) 0 1.43 (1.80)
Three years after the first IVR 2.91 (5.41) 0.55 (0.35) 3.36 (5.79)
Change value 1.69 (5.04) 0.55 (0.35) 1.92 (5.47)
RPE atrophy area in fellow eyes (mm2)
Baseline 0.93 (1.33) 0.02 (0.01) 1.09 (1.95)
Three years after the first IVR 1.14 (1.69) 0.24 (0.60) 1.31 (2.24)
Change value 0.22 (0.79) 0.22 (0.64) 0.22 (1.05)
Visual acuity (logMAR value)
Baseline 0.33 (0.36) 0.31 (0.09) 0.33 (0.39)
Three years after the first IVR 0.23 (0.31) 0.19 (0.22) 0.25 (0.32)
Change value 0.10 (0.25) 0.12 (0.14) 0.08 (0.28)
PCV lesion area (mm2) at baseline 2.93 (1.60) 2.46 (0.99) 3.02 (1.68)
No. injections during three years 11.4 (4.50) 10.3 (3.51) 11.6 (4.82)
SD standard deviation, RPE retinal pigment epithelium, logMAR logarithm of the minimum angle of resolution, IVR intravitreal injection of ranibizumab, PCV
polypoidal choroidal vasculopathy
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significantly (P = 0.001) faster compared to that in the
fellow eyes [0.07 (0.28 mm2)].
Univariate analysis showed that advancing age, worse
baseline VA, larger PCV lesions at baseline, and larger
RPE atrophic areas at baseline in the treated eyes were
the risk factors for increased RPE atrophic areas during
ranibizumab therapy (Table 2). The number of IVR dur-
ing 3-year follow-up period was not associated with in-
creased RPE atrophic areas. Stepwise regression analysis
showed that larger PCV lesions and larger RPE atrophic
areas at baseline were associated significantly (adjusted
R2 = 0.43, P = 0.001) with increased RPE atrophy areas
during 3-year follow-up period of ranibizumab mono-
therapy (Table 3).
The RPE area overlapping the baseline PCV lesions
significantly increased from 0.98 (1.87 mm2) to 2.53
(5.86 mm2) 3 years after the first IVR (P = 0.016),
whereas the RPE area not overlapping the baseline PCV
lesions changed from 0.21 (0.46 mm2) to 0.40
(0.77 mm2), which did not differ significantly (Fig. 2).
The baseline ICGA images showed polypoidal lesions
in all 100 eyes. No polypoidal lesions were detected on
ICGA images in 22 (22 %) eyes 3 years after the first
IVR. Regarding the changes in the RPE atrophic area
during the follow-up period, no apparent difference was
found between eyes with and without resolution of
polypoidal lesions (Table 4). Branching vascular net-
works remained in all eyes on ICGA images 3 years after
the first IVR. In eyes with worse VA 3 years after the
first IVR, increased RPE atrophic area significantly larger
(P = 0.027) (Table 4).
There was relatively good reproducibility (interclass
correlation, 0.89; 95 % confidence interval, 0.79-0.96) be-
tween the two examiners who measured RPE atrophic
areas. The intra-examiner agreement also was good
(intraclass correlation, 0.94; 95 % confidence interval,
0.86-0.97).
During the follow-up period, no endophthalmitis, uve-
itis, lens damage, or prolonged intraocular pressure ele-
vation occurred during the study period.
Discussion
In the current study, we investigated the quantitative
changes in RPE atrophy in eyes with PCV treated with
ranibizumab through an as-needed protocol and found
significant enlargement of RPE atrophy areas. Further-
more, larger PCV lesions and RPE atrophic areas at
baseline predicted progressing RPE atrophic areas during
ranibizumab therapy. Since larger areas have a longer
border, and deterioration of RPE cells adjacent to RPE
atrophic areas may occur, larger RPE atrophic areas at
baseline may be correlated with the risk for progressing
RPE atrophic areas during the follow-up period. More-
over, the most notable result of the current study was a
tendency for progression of RPE atrophy over PCV le-
sions during ranibizumab therapy. This finding explains
that larger PCV lesions at baseline predict progressing
RPE atrophy.
Although the mean VA improved during 3-year
follow-up of this study in spite of increased RPE atro-
phic area, worse VA 3 years after the first IVR correlated
with larger area of RPE atrophy. Although clinical
Fig. 1 Mean area (mm2) of retinal pigment epithelial atrophy at various points during the follow-up period. RPE = retinal pigment epithelium.
Error bars show standard error
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Table 2 Univariate analysis for the association between each factor and increased retinal pigment epithelial atrophic area (mm2)
during the follow-up period of three years
No. Increased RPE atrophic area (mm2) in treated eyes [Mean (SD)] P value
Age (years) 0.014*
≦69 42 1.21 (4.00)
70-79 34 1.72 (3.98)
≧80 24 2.10 (3.97)
Gender 0.671†
Female 48 1.67 (4.25)
Male 52 1.71 (4.96)
Baseline decimal VA 0.024*
≧0.5 70 1.65 (5.08)
0.2 - 0.4 20 2.44 (3.51)
≦0.1 10 3.58 (3.15)
PCV lesion area (DA) 0.001*
≦1 29 1.34 (3.79)
> 1 to ≦2 39 1.45 (3.88)
> 2 to 4 17 2.08 (3.92)
> 4 15 2.57 (3.94)
PED at baseline 0.576†
No 68 1.58 (4.33)
Yes 32 1.83 (4.36)
Hemorrhage at baseline 0.639†
No 78 1.60 (4.15)
Yes 22 1.77 (3.85)
Area of RPE atrophy at baseline (DA) 0.003*
Incident 16 0.55 (0.35)
Prevalent 84 1.92 (5.47)
≦0.5 44 1.53 (2.95)
> 0.5 to 1 20 2.07 (3.12)
> 1 20 2.59 (3.92)
Area of RPE atrophy in fellow eye at baseline (DA) 0.967*
≦0.5 39 1.55 (3.41)
> 0.5 61 1.77 (4.07)
Location of PCV lesion 0.928†
Subfoveal 88 1.70 (5.24)
Not subfoveal 12 1.65 (3.95)
Intraretinal fluid at baseline 0.657‡
None 11 1.73 (3.46)
Not subfoveal 6 2.08 (2.15)
Subfovea 83 1.67 (4.64)
Subretinal fluid at baseline 0.687‡
None 76 1.67 (3.31)
Not subfoveal 6 1.72 (3.62)
Subfovea 18 1.86 (3.93)
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examination of AMD have indicated that the fovea tend
to remain uninvolved by the RPE atrophic process until
late in the disease course and follow-up period of anti-
VEGF therapy [13, 14, 19], because RPE atrophy seems
to progress over time [12], the long-term effect of these
treatments on the central VA needs to be ascertained for
the long term.
Although the current study did not directly address any
causal relationship such as whether anti-VEGF treatment
itself causes acceleration of RPE atrophy in PCV or
whether development of RPE atrophy is part of the under-
lying disease progression of PCV, the results indicated that
RPE atrophy tends to progress over PCV lesions and the
total number of injections was not associated significantly
with the quantitative amount of progressing RPE atrophy
during ranibizumab therapy. Spectral-domain OCT im-
ages obtained from eyes with PCV showed that branching
choroidal vascular networks and polypoidal lesions exist
between the RPE and Bruch’s membrane and adhere to
the back surface of the RPE layers [20]. Yamagishi et al.
[7] described two characteristic patterns of hypoautofluor-
escence on FAF images compared with ICGA images, i.e.,
the well-demarcated confluent hypoautofluorescence cor-
responding to the polyp and heterogeneous granular
hypoautofluorescence consistent with branching vascular
networks on ICGA images, and suggested that in eyes
with PCV, the presence of a neovascular lesion may dir-
ectly affect the overlying RPE cells. Sato et al. [21] re-
ported the “double layer sign” in eyes with PCV
corresponding to the branching choroidal vascular net-
works and fluid accumulation between the RPE and
Bruch’s membrane. Similar to the polypoidal lesions, the
branching choroidal vascular networks seem to have an
exudative property and may have a significant
hemodynamic effect on the RPE layer. In addition, even
without exudative changes, the presence of a branching
vascular network adhering to the back surface of the RPE
layers may be associated with RPE atrophy.
RPE-derived VEGF plays an essential role in maintenance
of the choriocapillaris and cone photoreceptors [8, 10]. A
study [10] of deletion of VEGF-A and VEGF isoforms in
adult mice have suggested that sustained VEGF antagonism
diminishes the trophic effects of RPE-produced VEGF, lead-
ing to exacerbation of RPE and choriocapillaris atrophy.
Ford et al. [8] also reported that VEGF plays a critical role
in survival and maintenance of RPE integrity and stated
that potential undesired off-target effects should be consid-
ered with chronic use of anti-VEGF agents. Conversely, in
Table 2 Univariate analysis for the association between each factor and increased retinal pigment epithelial atrophic area (mm2)
during the follow-up period of three years (Continued)
Number of IVR during 3-year follow-up period 0.336*
1-5 8 1.69 (2.71)
6-10 36 1.68 (3.86)
11-15 42 1.70 (4.25)
≧16 14 1.66 (2.25)
Polypoidal lesions three years after the first IVR 0.871†
Detection 78 1.68 (4.45)
No detection 22 1.72 (4.73)
Decimal VA three years after the first IVR 0.016*
≧0.5 78 1.39 (4.83)
0.2 - 0.4 15 2.44 (3.86)
≦0.1 7 3.31 (2.29)
RPE retinal pigment epithelium, SD standard deviation, VA visual acuity, PCV polypoidal choroidal vasculopathy, DA disc area, PED pigment epithelial detachment,
IVR intravitreal ranibizumab injection
*, simple regression analysis; †, Student’s t-test; ‡, one-way analysis of variance test
Table 3 Stepwise regression analysis of risk factors for increased areas of retinal pigment epithelial atrophy during three-year follow-
up period of ranibizumab monotherapy
Characteristic Standardized regression coefficient 95 % confidence interval P value
Baseline PCV area 0.32 0.23 to 0.40 0.001
Baseline RPE
atrophic area 0.379 0.32 to 0.45 0.001
Larger PCV lesions and larger RPE atrophic areas at baseline are associated significantly (adjusted R2 = 0.43, P = 0.001) with increased RPE atrophic areas during
ranibizumab therapy
PCV polypoidal choroidal vasculopathy, RPE retinal pigment epithelium
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the reports [13, 14] from the CATT Research Group, al-
though a larger number of injections was associated with
increased risk of GA development in the CATT study, once
GA developed, the growth rate was not associated signifi-
cantly with the number of injections. The reasons for this
discrepancy were not discussed. In the current study, the
total number of injections was not associated significantly
with the quantitative amount of progressing RPE atrophy
during ranibizumab therapy. Further clinical studies are ne-
cessary to confirm the relationship between the RPE dam-
age and the number of anti-VEGF injections.
Resolution or persistence of polypoidal lesions that
responded to ranibizumab therapy was not associated with
the size of the increased area of RPE atrophy during the
follow-up period in the current study. Yamagishi et al. [6]
reported that at the follow-up examination, the baseline
confluent and granular hypoautofluorescence of FAF was
unchanged, even after complete regression of exudation
and resolution of the polypoidal lesions. We think that
since RPE atrophy tends to progress over PCV lesions in-
cluding polypoidal lesions and branching vascular net-
works and areas of branching vascular networks are
generally larger than those of PCV lesions, the effect of
resolution or no resolution of the polypoidal lesions on
the changes in RPE atrophy area may be relatively small in
total RPE atrophic area.
Conclusions
The limitations of the current study included its retro-
spective nature and the relatively small number of pa-
tients. Another limitation is that the current study did
not directly address any causal relationship such as
whether anti-VEGF treatment itself causes acceleration
of RPE atrophy or whether development of RPE atrophy
is part of the underlying disease progression of PCV.
Despite these shortcomings, the study found progressing
RPE atrophy in eyes with PCV during ranibizumab
monotherapy and the tendency for development of RPE
atrophy within the PCV lesions. This information may
guide future treatment strategies for PCV, such as the
need to protect the RPE cells to maintain the improved
VA after the treatment over the long term.
Ethics and content to participate
The current research followed the tenets of the Declar-
ation of Helsinki, and all patients provided informed
consent after explanation of the study protocol. The in-
stitutional review board at Ohtsuka Eye Hospital ap-
proved this retrospective study.
Fig. 2 Progression of retinal pigment epithelial atrophy (RPE) over polypoidal choroidal vasculopathy (PCV) lesion during ranibizumab therapy. a
An indocyanine green angiography (ICGA) image at baseline. White arrows indicate the area of PCV lesions including polypoidal lesions and
branching vascular networks. b A fundus autofluorescence (FAF) image at baseline. White arrows indicate the area of RPE atrophy. c A native FAF
image at month 36. White arrows indicate the area of RPE atrophy, which enlarges over PCV lesion compared to the baseline area
Table 4 Correlation between Retinal Pigment Epithelial
Atrophic Area Three years After the First ranibizumab injection
and Resolution of Polypoidal lesions or Visual Acuity Three years
After the First ranibizumab injection
Increased RPE
atrophic area (mm2)
No. (Mean ± SD) P Value
Polypoidal lesions three years
after the first IVR
0.871
Detection 78 1.68 ± 4.45
No detection 22 1.72 ± 4.73
Decimal VA three years after
the first IVR
0.027
≧0.5 78 1.39 ± 4.83
0.2 - 0.4 15 2.44 ± 3.86
≦0.1 7 3.31 ± 2.29
SD standard deviation, IVR intravitreal ranibizumab injection; VA visual acuity
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